Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Vijver, Yudong He, L. Veer, H. Dai, A. Hart, D. Voskuil, G. Schreiber, J. Peterse, C. Roberts, M. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, Tony Velde, H. Bartelink, S. Rodenhuis, E. Rutgers, S. Friend, René Bernards (2002)
A gene-expression signature as a predictor of survival in breast cancer.The New England journal of medicine, 347 25
E. Millar, P. Graham, S. O'toole, C. McNeil, L. Browne, A. Morey, Sarah Eggleton, J. Beretov, C. Theocharous, A. Capp, E. Nasser, J. Kearsley, G. Delaney, G. Papadatos, C. Fox, R. Sutherland (2009)
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
G. Freedman, P. Anderson, Tianyu Li, N. Nicolaou (2009)
Locoregional recurrence of triple‐negative breast cancer after breast‐conserving surgery and radiationCancer, 115
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
L. Carey, C. Perou, C. Livasy, L. Dressler, D. Cowan, K. Conway, G. Karaca, M. Troester, C. Tse, S. Edmiston, Sandra Deming, J. Geradts, M. Cheang, T. Nielsen, P. Moorman, H. Earp, R. Millikan (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA, 295 21
M. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. Chia, C. Perou, T. Nielsen (2008)
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 14
N. Kroman, H. Holtveg, J. Wohlfahrt, M. Jensen, H. Mouridsen, M. Blichert‐Toft, M. Melbye (2004)
Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinomaCancer, 100
Ingrid Hedenfalk, Ingrid Hedenfalk, Dave Duggan, Yidong Chen, M. Radmacher, M. Bittner, R. Simon, P. Meltzer, B. Gusterson, M. Esteller, M. Raffeld, Z. Yakhini, A. Ben-Dor, E. Dougherty, J. Kononen, L. Bubendorf, Wilfrid Fehrle, S. Pittaluga, Sofia Gruvberger, N. Loman, O. Johannsson, Hampus Olsson, B. Wilfond, G. Sauter, O. Kallioniemi, Å. Borg, J. Trent (2001)
Gene-expression profiles in hereditary breast cancer.The New England journal of medicine, 344 8
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
A. Voogd, M. Nielsen, J. Peterse, M. Blichert‐Toft, H. Bartelink, M. Overgaard, G. Tienhoven, K. Andersen, R. Sylvester, J. Dongen (2001)
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 6
M. Kyndi, F. Sørensen, H. Knudsen, M. Overgaard, H. Nielsen, J. Overgaard (2008)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 9
Catherine Park, M. Mitsumori, A. Nixon, A. Recht, J. Connolly, R. Gelman, B. Silver, S. Hetelekidis, A. Abner, J. Harris, S. Schnitt (2000)
Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 8
S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, F. Baehner, D. Watson, J. Bryant, J. Costantino, C. Geyer, D. Wickerham, N. Wolmark (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 23
C. Anders, D. Hsu, G. Broadwater, C. Acharya, J. Foekens, Yi Zhang, Yixin Wang, P. Marcom, J. Marks, P. Febbo, J. Nevins, A. Potti, K. Blackwell (2008)
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 20
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
C. Fan, D. Oh, L. Wessels, B. Weigelt, D. Nuyten, A. Nobel, L. Veer, C. Perou (2006)
Concordance among gene-expression-based predictors for breast cancer.The New England journal of medicine, 355 6
S. Anderson, I. Wapnir, J. Dignam, B. Fisher, E. Mamounas, Jong-Hyeon Jeong, C. Geyer, D. Wickerham, J. Costantino, N. Wolmark (2009)
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15
B. Kreike, H. Halfwerk, N. Armstrong, P. Bult, J. Foekens, S. Veltkamp, D. Nuyten, H. Bartelink, M. Vijver (2009)
Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of PatientsClinical Cancer Research, 15
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
DS Nuyten, B Kreike, AA Hart (2006)
Predicting a local recurrence after breast-conserving therapy by gene expression profilingBreast Cancer Res, 8
K. Albain, W. Barlow, S. Shak, G. Hortobagyi, R. Livingston, I. Yeh, P. Ravdin, R. Bugarini, F. Baehner, N. Davidson, G. Sledge, E. Winer, C. Hudis, J. Ingle, E. Perez, K. Pritchard, L. Shepherd, J. Gralow, C. Yoshizawa, D. Allred, C. Osborne, D. Hayes (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.The Lancet. Oncology, 11 1
C. Livasy, G. Karaca, R. Nanda, M. Tretiakova, O. Olopade, D. Moore, C. Perou (2006)
Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaModern Pathology, 19
E. Rakha, J. Reis-Filho, I. Ellis (2008)
Basal-like breast cancer: a critical review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
B. Haffty, Qifeng Yang, M. Reiss, T. Kearney, S. Higgins, J. Weidhaas, L. Harris, W. Hait, D. Toppmeyer (2006)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
I. Fredriksson, G. Liljegren, M. Palm-Sjövall, L. Arnesson, S. Emdin, T. Fornander, A. Lindgren, H. Nordgren, I. Idvall, M. Holmqvist, L. Holmberg, J. Frisell (2003)
Risk factors for local recurrence after breast‐conserving surgeryBritish Journal of Surgery, 90
P. Nguyen, A. Taghian, M. Katz, A. Niemierko, R. Raad, Whitney Boon, J. Bellon, J. Wong, Barbara Smith, J. Harris (2008)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
S. Cheng, C. Horng, M. West, Erich Huang, J. Pittman, M. Tsou, H. Dressman, C. Chen, S. Tsai, J. Jian, Mei-Chin Liu, J. Nevins, A. Huang (2006)
Genomic prediction of locoregional recurrence after mastectomy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 28
J. Borger, H. Kemperman, A. Hart, H. Peterse, J. Dongen, H. Bartelink (1994)
Risk factors in breast-conservation therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 4
M. Clarke, R. Collins, S. Darby, C. Davies, P. Elphinstone, V. Evans, J. Godwin, R. Gray, C. Hicks, S. James, E. Mackinnon, P. Mcgale, T. McHugh, R. Peto, Carolyn Taylor, Yaochen Wang (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 366
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
The identification of genomic subtypes of breast cancer nearly 10 years ago provided powerful insight into the genetic heterogeneity of the disease. In the decade since, the concept of tumor biology has been shown to be highly relevant for determining survival outcomes and response to therapy, as well as in explaining variations in the disease noted clinically among women of different ages and races. Establishing tumor subtypes has also driven efforts to identify underlying pathways that drive the biologic phenotype and that can potentially be targeted therapeutically. However, far less is known about the impact of biologic subtypes on local regional outcomes and whether the same subtype specific biologic properties identified in the setting of distant disease can be translated to the local-regional context. In this review, we summarize current research in this area.
Current Breast Cancer Reports – Springer Journals
Published: Apr 13, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.